Literature DB >> 24325913

FAT10, an ubiquitin-like protein, confers malignant properties in non-tumorigenic and tumorigenic cells.

Yun Gao1, Steven Setiawan Theng, Jingli Zhuo, Wei Bing Teo, Jianwei Ren, Caroline G L Lee.   

Abstract

FAT10 (HLA-F-adjacent transcript 10) is an ubiquitin-like modifier, which has been implicated in immune response and cancer development. In particular, the hypothesis of FAT10 as a mediator of tumorigenesis stems from its ability to associate with a spindle checkpoint protein Mad2 during mitosis and cause aneuploidy, a hallmark of cancer cells. Furthermore, FAT10 is overexpressed in several carcinomas types, including that of liver and colon. Nevertheless, direct evidence linking FAT10 to cell malignant transformation and progression is lacking. Here, we demonstrate that high FAT10 expression enhanced the proliferative, invasive, migratory and adhesive functions of the transformed cell line, HCT116. These observations were consistently demonstrated in an immortalized, non-tumorigenic liver cell line NeHepLxHT. Importantly, FAT10 can induce malignant transformation as evidenced from the anchorage-independent growth as well as in vivo tumor-forming abilities of FAT10-overexpressing NeHepLxHT cells, whereas in rapidly proliferating HCT116, increased FAT10 further augmented tumor growth. FAT10 was found to activate nuclear factor-κB (NFκB), which in turn upregulated the chemokine receptors CXCR4 and CXCR7. Importantly, small interfering RNA depletion of CXCR7 and CXCR4 attenuated cell invasion of FAT10-overexpressing cells, indicating that the CXCR4/7 is crucial for the FAT10-dependent malignant phenotypes. Taken together, our data reveal novel functions of FAT10 in malignant transformation and progression, via the NFκB-CXCR4/7 pathway.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24325913     DOI: 10.1093/carcin/bgt407

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  21 in total

1.  Transcriptome profiling of the cancer and adjacent nontumor tissues from cervical squamous cell carcinoma patients by RNA sequencing.

Authors:  Guo Peng; Wang Dan; Wu Jun; Yang Junjun; Ren Tong; Zhu Baoli; Xiang Yang
Journal:  Tumour Biol       Date:  2015-01-14

2.  Disruption of FAT10-MAD2 binding inhibits tumor progression.

Authors:  Steven Setiawan Theng; Wei Wang; Way-Champ Mah; Cheryl Chan; Jingli Zhuo; Yun Gao; Haina Qin; Liangzhong Lim; Samuel S Chong; Jianxing Song; Caroline G Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-24       Impact factor: 11.205

3.  FAT10 promotes hepatocellular carcinoma (HCC) carcinogenesis by mediating P53 degradation and acts as a prognostic indicator of HCC.

Authors:  Yue Zhang; Zhifan Zuo; Bo Liu; Pinghua Yang; Jun Wu; Lei Han; Tao Han; Tingsong Chen
Journal:  J Gastrointest Oncol       Date:  2021-08

Review 4.  Technical standards for hepatitis B virus X protein (HBx) research.

Authors:  Betty L Slagle; Ourania M Andrisani; Michael J Bouchard; Caroline G L Lee; J-H James Ou; Aleem Siddiqui
Journal:  Hepatology       Date:  2015-03-09       Impact factor: 17.425

5.  TLR3/4 signaling is mediated via the NFκB-CXCR4/7 pathway in human alcoholic hepatitis and non-alcoholic steatohepatitis which formed Mallory-Denk bodies.

Authors:  Hui Liu; Jun Li; Brittany Tillman; Timothy R Morgan; Barbara A French; Samuel W French
Journal:  Exp Mol Pathol       Date:  2014-07-02       Impact factor: 3.362

Review 6.  Ubiquitin and Ubiquitin-like proteins in cardiac disease and protection.

Authors:  Jie Li; John A Johnson; Huabo Su
Journal:  Curr Drug Targets       Date:  2018       Impact factor: 3.465

7.  IL-8 signaling is up-regulated in alcoholic hepatitis and DDC fed mice with Mallory Denk Bodies (MDBs) present.

Authors:  Hui Liu; Barbara A French; Tyler J Nelson; Jun Li; Brittany Tillman; Samuel W French
Journal:  Exp Mol Pathol       Date:  2015-08-08       Impact factor: 3.362

8.  Different roles of FAT10, FOXO1, and ADRA2A in hepatocellular carcinoma tumorigenesis in patients with alcoholic steatohepatitis (ASH) vs non-alcoholic steatohepatitis (NASH).

Authors:  Yue Jia; Barbara French; Brittany Tillman; Samuel French
Journal:  Exp Mol Pathol       Date:  2018-07-17       Impact factor: 3.362

9.  Immortalized Human Hepatic Cell Lines for In Vitro Testing and Research Purposes.

Authors:  Eva Ramboer; Tamara Vanhaecke; Vera Rogiers; Mathieu Vinken
Journal:  Methods Mol Biol       Date:  2015

Review 10.  Strategies for immortalization of primary hepatocytes.

Authors:  Eva Ramboer; Bram De Craene; Joery De Kock; Tamara Vanhaecke; Geert Berx; Vera Rogiers; Mathieu Vinken
Journal:  J Hepatol       Date:  2014-06-06       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.